|
1
|
Shiozaki EN and Shi Y: Caspases, IAPs and
Smac/DIABLO: mechanisms from structural biology. Trends Biochem
Sci. 29:486–494. 2004.
|
|
2
|
Cheung HH, LaCasse EC and Korneluk RG:
X-linked inhibitor of apoptosis antagonism: strategies in cancer
treatment. Clin Cancer Res. 12:3238–3242. 2006.
|
|
3
|
Srinivasula SM, Hegde R, Saleh A, et al: A
conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO
regulates caspase activity and apoptosis. Nature. 410:112–116.
2001.
|
|
4
|
Song Z, Yao X and Wu M: Direct interaction
between survivin and Smac/DIABLO is essential for the
anti-apoptotic activity of survivin during taxol-induced apoptosis.
J Biol Chem. 278:23130–23140. 2003.
|
|
5
|
Miura K, Fujibuchi W, Ishida K, et al:
Inhibitor of apoptosis protein family as diagnostic markers and
therapeutic targets of colorectal cancer. Surg Today. 41:175–182.
2011.
|
|
6
|
Grzybowska-Izydorczyk O, Cebula B, Robak T
and Smolewski P: Expression and prognostic significance of the
inhibitor of apoptosis protein (IAP) family and its antagonists in
chronic lymphocytic leukaemia. Eur J Cancer. 46:800–810. 2010.
|
|
7
|
Wrzesień-Kuś A, Smolewski P, Sobczak-Pluta
A, Wierzbowska A and Robak T: The inhibitor of apoptosis protein
family and its antagonists in acute leukemias. Apoptosis.
9:705–715. 2004.
|
|
8
|
Yoo NJ, Kim HS, Kim SY, et al:
Immunohistochemical analysis of Smac/DIABLO expression in human
carcinomas and sarcomas. APMIS. 111:382–388. 2003.
|
|
9
|
Endo K, Kohnoe S, Watanabe A, et al:
Clinical significance of Smac/DIABLO expression in colorectal
cancer. Oncol Rep. 21:351–355. 2009.
|
|
10
|
Yan H, Yu J, Wang R, Jiang S, Zhu K, Mu D
and Xu Z: Prognostic value of Smac expression in rectal cancer
patients treated with neoadjuvant therapy. Med Oncol. 29:168–173.
2012.
|
|
11
|
Zheng LD, Tong QS, Wang L, Liu J and Qian
W: Stable transfection of extrinsic Smac gene enhances
apoptosis-inducing effects of chemotherapeutic drugs on gastric
cancer cells. World J Gastroenterol. 11:79–83. 2005.
|
|
12
|
Li F: Survivin study: what is the next
wave? J Cell Physiol. 197:8–29. 2003.
|
|
13
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997.
|
|
14
|
Liston P, Fong WG and Korneluk RG: The
inhibitors of apoptosis: there is more to life than Bcl2. Oncogene.
22:8568–8580. 2003.
|
|
15
|
Li F, Ackermann EJ, Bennett CF, et al:
Pleiotropic cell-division defects and apoptosis induced by
interference with survivin function. Nat Cell Biol. 1:461–466.
1999.
|
|
16
|
Knauer SK, Mann W and Stauber RH:
Survivin’s dual role: an export’s view. Cell Cycle. 6:518–521.
2007.
|
|
17
|
Sah NK, Khan Z, Khan GJ and Bisen PS:
Structural, functional and therapeutic biology of survivin. Cancer
Lett. 244:164–171. 2006.
|
|
18
|
Andersen MH, Svane IM, Becker JC and
Straten PT: The universal character of the tumor-associated antigen
survivin. Clin Cancer Res. 13:5991–5994. 2007.
|
|
19
|
Choi J and Chang H: The expression of MAGE
and SSX, and correlation of COX2, VEGF, and survivin in colorectal
cancer. Anticancer Res. 32:559–564. 2012.
|
|
20
|
Wang TT, Qian XP and Liu BR: Survivin:
potential role in diagnosis, prognosis and targeted therapy of
gastric cancer. World J Gastroenterol. 13:2784–2790. 2007.
|
|
21
|
Kerr JF, Winterford CM and Harmon BV:
Apoptosis. Its significance in cancer and cancer therapy. Cancer.
73:2013–2026. 1994.
|
|
22
|
Reed JC: Mechanisms of apoptosis. Am J
Pathol. 157:1415–1430. 2000.
|
|
23
|
Lavrik IN, Golks A and Krammer PH:
Caspases: pharmacological manipulation of cell death. J Clin
Invest. 115:2665–2672. 2005.
|
|
24
|
Shintani M, Sangawa A, Yamao N, Miyake T
and Kamoshida S: Immunohistochemical analysis of cell death
pathways in gastrointestinal adenocarcinoma. Biomed Res.
32:379–386. 2011.
|
|
25
|
Shintani M, Sangawa A, Yamao N and
Kamoshida S: Immunohistochemical expression of nuclear and
cytoplasmic survivin in gastrointestinal carcinoma. Int J Clin Exp
Pathol. 6:2919–2927. 2013.
|
|
26
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumours. 7th edition.
Wiley-Blackwell; New Jersey: 2009
|
|
27
|
Kim MA, Lee HE, Lee HS, Yang HK and Kim
WH: Expression of apoptosis-related proteins and its clinical
implication in surgically resected gastric carcinoma. Virchows
Arch. 459:503–510. 2011.
|
|
28
|
Shibata T, Noguchi T, Takeno S, Gabbert
HE, Ramp U and Kawahara K: Disturbed XIAP and XAF1 expression
balance is an independent prognostic factor in gastric
adenocarcinomas. Ann Surg Oncol. 15:3579–3587. 2008.
|
|
29
|
DA Silva LC, Forones NM, Ribeiro DA, Ihara
SS, Gomes TS, Neto RA and Oshima CT: Immunoexpression of DIABLO,
AIF and cytochrome C in gastric adenocarcinoma assessed by tissue
Microarray. Anticancer Res. 33:647–653. 2013.
|
|
30
|
De Oliveira Lima F, De Oliveira Costa H,
Barrezueta LF, et al: Immunoexpression of inhibitors of apoptosis
proteins and their antagonist SMAC/DIABLO in colorectal carcinoma:
correlation with apoptotic index, cellular proliferation and
prognosis. Oncol Rep. 22:295–303. 2009.
|
|
31
|
Fang YJ, Lu ZH, Wang GQ, et al: Elevated
expressions of MMP7, TROP2, and survivin are associated with
survival, disease recurrence, and liver metastasis of colon cancer.
Int J Colorectal Dis. 24:875–884. 2009.
|
|
32
|
Okada E, Murai Y, Matsui K, Isizawa S,
Cheng C, Masuda M and Takano Y: Survivin expression in tumor cell
nuclei is predictive of a favorable prognosis in gastric cancer
patients. Cancer Lett. 163:109–116. 2001.
|
|
33
|
Stauber RH, Mann W and Knauer SK: Nuclear
and cytoplasmic survivin: molecular mechanism, prognostic, and
therapeutic potential. Cancer Res. 67:5999–6002. 2007.
|
|
34
|
Ponnelle T, Chapusot C, Martin L, et al:
Cellular localisation of survivin: impact on the prognosis in
colorectal cancer. J Cancer Res Clin Oncol. 131:504–510. 2005.
|
|
35
|
Qi G, Tuncel H, Aoki E, et al:
Intracellular localization of survivin determines biological
behavior in colorectal cancer. Oncol Rep. 22:557–562. 2009.
|
|
36
|
Lee YY, Yu CP, Lin CK, Nieh S, Hsu KF,
Chiang H and Jin JS: Expression of survivin and cortactin in
colorectal adenocarcinoma: association with clinicopathological
parameters. Dis Markers. 26:9–18. 2009.
|
|
37
|
Vallböhmer D, Drebber U, Schneider PM, et
al: Survivin expression in gastric cancer: Association with
histomorphological response to neoadjuvant therapy and prognosis. J
Surg Oncol. 99:409–413. 2009.
|
